A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-13

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792

Glioblastoma Glioblastoma Multiforme

ACTIVE_NOT_RECRUITING PHASE1

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

NCT01752491

Glioblastoma GBM Glioblastoma Multiforme

COMPLETED PHASE1

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT02168270

Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma +2 more

TERMINATED PHASE1

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701

Glioblastoma Glioma

TERMINATED PHASE1

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

NCT01062425

Adult Glioblastoma Adult Gliosarcoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth). After radiation, patients receive additional cycles of temozolomide (adjuvant chemotherapy).

Participants will:

* receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase
* receive high doses of intravenous (IV) ascorbate twice a week during adjuvant chemotherapy (after radiation)
* complete health-related quality of life questionnaires pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and approximately 9 months after initiating radiation therapy.

The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Multiforme

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ascorbate, radiation, temozolomide

Concomitant therapy:

Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions

Adjuvant therapy:

Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions

Group Type EXPERIMENTAL

Temozolomide

Intervention Type DRUG

oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.

Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.

For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.

If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.

radiation therapy

Intervention Type RADIATION

Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.

Ascorbic Acid

Intervention Type DRUG

Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.

After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide

oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.

Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.

For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.

If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.

Intervention Type DRUG

radiation therapy

Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.

Intervention Type RADIATION

Ascorbic Acid

Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.

After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Temodar Temodal EBRT XRT external beam radiation therapy Vitamin C Ascorbate Pharmacological Ascorbate 67457-118-50

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand and willingness to sign informed consent (power of attorney and/or legally authorized representatives cannot sign on behalf of the patient)
* Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme.
* Diagnosis must be made by surgical biopsy or excision.
* Therapy must begin ≤ 5 weeks after surgery or biopsy
* Age ≥ 18 years
* ECOG performance status 0-2. (KPS \> 50)
* Absolute neutrophil count (ANC) ≥ 1500 cells per mm3
* Platelets ≥ 100,000 per mm3
* Hemoglobin ≥ 8 g/dL
* Creatinine ≤ 2.0 mg
* Total bilirubin ≤ 1.5 mg/dL
* ALT ≤ 3 times the institutional upper limit of normal
* AST ≤ 3 times the institutional upper limit of normal
* Tolerate one test dose (15g) of ascorbate.
* Not pregnant.

Exclusion Criteria

* Recurrent high grade glioma
* G6PD (glucose-6-phosphate dehydrogenase) deficiency.
* Patients actively receiving insulin or using a finger-stick glucometer daily for blood glucose measurements
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.
* Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.
* Patients who are on the following drugs and cannot have a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.
* Known active concurrent malignancy, as determined by treating physicians.
* Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.
* Prior radiation therapy to the head or neck resulting in overlap of RT fields.
* Patients receiving any other investigational agents (imaging agents are acceptable)
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would result in a hospital stay or delay of treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or impact patient safety.
* Pregnant women.
* Breastfeeding women.
* Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No